Abstract:Objectives Acute hemorrhage can cause significant morbidity and mortality arising from trauma, bleeding disorders, surgical procedures, or obstetric complications. Surgical hemostasis methods may fail to stop acute bleeding due to the complex bleeding dynamics of each bleeding type. Therefore, developing safe and effective topical hemostatic agents remains crucial. The human amniotic membrane (hAM) has established clinical evidence of effectiveness in promoting wound healing and tissue regeneration. Despite its unique biological and immunologic properties and its structural composition of established hemostatic elements, the hemostatic role of hAM has not been yet explored. The present study aimed to investigate this potential role and to describe the development protocol and characterization of hAM‐derived topical hemostat. Methods Surface electron microscope (SEM) imaging and Fourier transform infrared (FTIR) spectroscopy were used for characterization, and mouse models with induced peritoneal and tail wound bleeding were employed to evaluate the hemostatic effectiveness using physiological studies, in comparison to a chitosan‐based combat‐scale hemostat. Results The hAM hemostat showed a distinctive composition by SEM and FTIR. Applying equal masses of the hAM hemostat, the commercial hemostat, or a combination reduced peritoneal wound bleeding time to averages of 108.4, 86.2, and 76.8 s, respectively, compared to the control group (300 s). Tail wound bleeding times were similarly reduced with no significant difference between the hAM and the commercial hemostat (P values = 0.29, 0.34 in peritoneal and tail wounds, respectively). Neither hemostat affected coagulation time. Conclusion This study describes a simple cost‐effective preparation protocol for a hAM‐based hemostatic agent. The long‐recognized safety, sustainability, and immunotolerance advantages of hAM can establish superiority over commercial hemostats with reported safety concerns. Robust research validation in larger‐scale bleeding models is required for wider applications and severe bleeding types.

Hemostats in the clinic

Hemostats, sealants, and adhesives: components of the surgical toolbox

Current status of hemostatic agents, their mechanism of action, and future directions

Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding

State of the art, trends, hotspots, and prospects of injection materials for controlling bleeding

Hemorrhage control in the battlefield: role of new hemostatic agents

Emerging materials for hemostasis

Hemorrhage Control: Lessons Learned From the Battlefield Use of Hemostatic Agents That Can Be Applied in a Hospital Setting

Polysaccharide-based hemostats: recent developments, challenges, and future perspectives

Emerging hemostatic materials for non-compressible hemorrhage control

Alginate based biomaterials for hemostatic applications: Innovations and developments

Recent research advances on polysaccharide-, peptide-, and protein-based hemostatic materials: A review

Hemostatic materials in wound care

S3808 Hemostatic Peptides: An Effective Tool for Managing Bleeding When Traditional Options Are Challenging

Use and Efficacy of Hemostats in Neurosurgery

Preparation and Application of Hemostatic Hydrogels

Advances of biological macromolecules hemostatic materials: A review

Prehospital Application of Hemostatic Agents in Iraq and Afghanistan

Recent Advances on Synthetic and Polysaccharide Adhesives for Biological Hemostatic Applications

Research status and development potential of composite hemostatic materials.

Potential novel role of the human amniotic membrane as a sustainable hemostat